These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10510111)

  • 21. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer?
    Goeman L; Joniau S; Ponette D; Van der Aa F; Roskams T; Oyen R; Van Poppel H
    Prostate Cancer Prostatic Dis; 2003; 6(4):305-10. PubMed ID: 14663472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies.
    Gallo F; Chiono L; Gastaldi E; Venturino E; Giberti C
    Urology; 2008 Sep; 72(3):628-32. PubMed ID: 18279918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia.
    Agarwal DK; Costello AJ; Peters J; Sikaris K; Crowe H
    BJU Int; 2000 Apr; 85(6):690-5. PubMed ID: 10759667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-grade intra-epithelial neoplasia and prostate cancer in Dibombari, Cameroon.
    Angwafo FF; Zaher A; Befidi-Mengue R; Wonkam A; Takougang I; Powell I; Murphy G;
    Prostate Cancer Prostatic Dis; 2003; 6(1):34-8. PubMed ID: 12664062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
    Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    España F; Royo M; Martínez M; Enguídanos MJ; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF; Heeb MJ
    J Urol; 1998 Dec; 160(6 Pt 1):2081-8. PubMed ID: 9817329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen.
    Morote J; Lopez M; Encabo G; de Torres IM
    Eur Urol; 2000 May; 37(5):537-40. PubMed ID: 10765091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia.
    García-Cruz E; Piqueras M; Ribal MJ; Huguet J; Serapiao R; Peri L; Izquierdo L; Alcaraz A
    BJU Int; 2012 Sep; 110(6 Pt B):E199-202. PubMed ID: 22257176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml.
    Morote J; Trilla E; Esquena S; Serrallach F; Abascal JM; Muñoz A; Id M'Hammed Y; de Torres IM
    Eur Urol; 2002 Oct; 42(4):333-7. PubMed ID: 12361897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy.
    Roscigno M; Scattoni V; Freschi M; Abdollah F; Maccagnano C; Galosi A; Lacetera V; Montironi R; Muzzonigro G; Deho F; Deiana G; Belussi D; Chinaglia D; Montorsi F; Da Pozzo LF
    BJU Int; 2012 May; 109(9):1329-34. PubMed ID: 21895935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer detection yield in repeated biopsy is independent of the diagnosis of earlier biopsies.
    Grepl M; Student V; Furst T; Furstova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Dec; 153(4):297-302. PubMed ID: 20208971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
    Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
    Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma?
    Raviv G; Zlotta AR; Janssen Th; Descamps F; Vanegas JP; Verhest A; Schulman CC
    Cancer; 1996 May; 77(10):2103-8. PubMed ID: 8640677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Goepel M; Tscholl R
    Br J Urol; 1998 Apr; 81(4):532-8. PubMed ID: 9598623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer.
    Fowke JH; Motley SS; Barocas DA; Cookson MS; Concepcion R; Byerly S; Smith JA
    Cancer Causes Control; 2011 Mar; 22(3):417-26. PubMed ID: 21170754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.